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Abstract
Background—Reducing HIV infection and improving outcomes along the continuum of HIV 
care are high priorities of the U.S. National HIV/AIDS Strategy. Interventions that target multiple 
problem behaviors simultaneously in an integrated approach (referred to as integrated 
interventions) may improve prevention and care outcomes of persons living with HIV (PLWH). 
This systematic review and meta-analysis examines the effects of integrated interventions.
Methods—A systematic review, including both electronic and hand searches, was conducted to 
identify randomized controlled trials (RCTs) published between 1996 and 2014 that were designed 
to target at least two of the following behaviors among PLWH: HIV transmission risk behaviors, 
HIV care engagement, and medication adherence. Effect sizes (ESs) were meta-analyzed using 
random-effects models.
Results—Fifteen RCTs met the inclusion criteria. Integrated interventions significantly reduced 
sex without condoms (odds ratio [OR] = 0.74, 95% CI = 0.59, 0.94, p = .013, 13 ESs) and had 
marginally significant effects on improving medication adherence behaviors (OR = 1.35, 95% CI 
= 0.98, 1.85, p = .063, 12 ESs) and undetectable viral load (OR = 1.46, 95% CI= 0.93, 2.27, p = .
098, 7 ESs). Significant intervention effects on at least two outcomes were seen in RCTs tailored 
to individual needs, delivered one-on-one, or in settings where PLWH received services or care.
Conclusions—Integrated interventions produced some favorable prevention and care continuum 
outcomes in PLWH. How to incorporate integrated interventions with other Combination HIV 
Prevention strategies to reach the optimal impact requires further research.
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INTRODUCTION
The National HIV/AIDS Strategy (NHAS)[1] outlines several goals for ending the domestic 
HIV epidemic, including use of evidence-based prevention strategies to reduce HIV 
transmission, increase access to care, and optimize health outcomes for persons living with 
HIV (PLWH). The most up-to-date estimates show that 1.2 million persons were living with 
HIV infection in the United States (U.S.) in 2012. Among these PLWH, 39% were engaged 
in HIV medical care, 36% were prescribed antiretroviral therapy (ART), and 30% achieved 
viral suppression [2]. These figures call for further improvements across the HIV care 
continuum in order to reach NHAS’ prevention and care goals.
Engaging in HIV medical care shortly after HIV diagnosis and sustaining routine care with 
high adherence to ART can improve health outcomes of PLWH and prevent HIV 
transmission [3]. Non-engagement in HIV care, non-adherence to ART, and non-adherence 
to safer sex can each have adverse health consequences for PLWH and their partners. 
Evidence also suggests these behaviors are associated with each other. Sexual risk among 
PLWH was found to be associated with not being engaged in HIV care [4] or not adhering to 
ART [5]. Non-engagement in HIV care was found to be associated with poor medication 
adherence and detectable viral load [6]. These associations suggest the need for 
interventions that target multiple behaviors to reduce HIV transmission and improve health 
outcomes of PLWH.
Intervening on multiple behaviors at one time strengthens the connection between 
prevention and care and is consistent with Combination HIV Prevention [3, 7]. Integrated 
interventions are defined here as interventions that target multiple behaviors of PLWH. By 
simultaneously addressing problem behaviors caused by similar influencing factors (e.g., 
motivation, knowledge, skills, stigma, mental health, homelessness), integrated interventions 
may be more practical and economical than interventions that target one behavior at a time 
(single-target interventions). However, addressing multiple behavioral targets may 
potentially dilute the intervention effects on any single outcome.
Before considering integrated interventions as part of Combination HIV Prevention, it is 
important to examine whether integrated interventions are effective in improving prevention 
and care outcomes. Several systematic reviews and meta-analyses have examined the effects 
of interventions that reduce behavioral risk of transmitting HIV [8-12], promote HIV care 
engagement and utilization [13, 14], and improve adherence to HIV medication and viral 
suppression [15-17] among PLWH. To our knowledge, there is no systematic review or 
meta-analysis that evaluates the effects of integrated interventions. In this meta-analysis, we 
systematically reviewed U.S.-based randomized controlled trials (RCTs) that evaluated 
integrated interventions specifically designed for PLWH and addressed at least two of the 
following behaviors: transmission risk behaviors, HIV care engagement, and medication 
adherence. Our goals are to describe the characteristics of currently available integrated 
interventions, assess intervention effects on prevention and care continuum outcomes, and 
identify research gaps to inform prevention and treatment efforts.
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METHODS
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement [18] to report our systematic review and meta-analysis. Supplementary 
Material A provides the PRISMA checklist. A study protocol is not available for this review.
Search Strategy
We used the CDC's Prevention Research Synthesis (PRS) project's cumulative HIV/
AIDS/STD research database for identifying relevant reports. The PRS database is updated 
annually following a well-established systematic search protocol, which consists of 
automated and manual searches [19]. Each year, four comprehensive searches are conducted 
to locate citations related to HIV risk reduction (RR), medication adherence (MA), linkage 
to and retention and re-engagement in HIV care (LRC), and systematic reviews of HIV 
prevention. All four searches include the electronic databases (and platforms): EMBASE 
(OVID), MEDLINE (OVID), and PsycINFO (OVID). Additional electronic databases (e.g., 
Sociological Abstracts, CINAHL, CAB Global Health) are included for some searches (see 
Supplementary Material B for detailed information).
Each comprehensive, automated search combines keywords and index terms used to 
describe concepts within a domain. For example, the RR search consists of three domains: 
(1) HIV, AIDS or STD index terms; (2) prevention, intervention or evaluation terms; and (3) 
behavior or outcome terms. The Boolean operator ‘OR’ is used to consolidate each domain 
with an ‘AND’ operator used to cross-reference each domain. No language restriction was 
applied to the automated search. The full search strategy of the MEDLINE database for each 
of the four comprehensive searches is provided as Supplementary Material C. The searches 
of the other databases are available from the corresponding author.
The manual search included three components: (a) quarterly searches of all reports 
published in the previous 3 months of 60 journals (see Supplementary Material D) to 
identify potentially relevant citations not yet indexed in electronic databases, (b) review of 
the reference lists of pertinent articles; and (c) searches of HIV/AIDS Internet listservs and 
other research databases (e.g., ISI Web of Knowledge, RePORTER, Cochrane Library).
Citations identified through automated and manual searches were downloaded and de-
duplicated in the PRS database before conducting title/abstract screening and full-report 
coding. The last date we searched the PRS database was January 2, 2015.
Inclusion Criteria
Inclusion criteria were randomized controlled trials that: (1) evaluated interventions 
specifically designed for PLWH; (2) were conducted in the U.S.; (3) were published or in 
press between 1996 and 2014; (5) tested interventions that addressed at least two of the 
behaviors: HIV transmission risk behaviors, HIV care engagement, or medication 
adherence; and (6) reported at least two of the following relevant outcomes:
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• Behaviors (i.e., sex without condoms, number of sex partners, needle sharing, 
injection drug use) or biological outcomes (i.e., STD) that increase HIV 
transmission risk,
• HIV care engagement (i.e., retention in HIV care measured by the number of 
missed or kept HIV care appointments or having 2 HIV medical visits within past 6 
months), and
• HIV medication adherence (i.e., being on ART, behavioral measures of adherence 
by medication event monitoring system [MEMS], electronic drug monitoring 
[EDM], pill count, pharmacy refill, or self-report; viral load level measured by self-
report or medical records).
Data Abstraction
Pairs of trained coders independently coded each eligible intervention using standardized 
coding forms for the following: study characteristics (e.g., study date, location, study design, 
sample size, data collection method), participant characteristics (e.g., target population, 
gender, race/ethnicity, sexual orientation), intervention characteristics (e.g., components, 
delivery method, duration, time span), outcomes, and risk of bias. Linked citations, defined 
as publications offering additional information on the same study, were included if they 
provided relevant intervention and evaluation information. The overall percentage 
agreement among trained coders is 96% with a kappa rate of 80%, indicating a high inter-
rater reliability. We contacted the primary study investigator to obtain additional 
information as needed. The response rate was 90%.
Because studies differ in reporting outcomes and findings, we applied the following rules for 
guiding data abstraction for analyses. For studies that reported multiple outcomes of interest, 
separate analyses were conducted for sex without condoms, number of sex partners, STD, 
needle sharing, injection drug use, taking ART, HIV care engagement, medication 
adherence and viral load suppression. This approach allowed us to examine intervention 
effects on different outcomes as the prevention literature showed some outcomes (e.g., 
number of sex partners, STD) were more difficult to change than other outcomes (e.g., sex 
without condoms) [9].
If sex behavior data for different types of partners were reported, the analysis focused on sex 
with at-risk partners (i.e., HIV-negative or status-unknown partners) rather than HIV-
positive or all partners. For studies that reported medication adherence outcomes based on 
self-report or MEMS data, the latter was used in the analysis. For studies that reported 
multiple follow-up assessments, we selected the time point closest to 3 months post 
completion of the intervention for interventions that are clearly discrete (i.e., all the sessions 
are thought to be necessary and sufficient for yielding the desired change) and the last 
assessment point for interventions that are designed to be on-going (i.e., receiving the 
intervention at each clinic visit). To reduce the impact of group differences at baseline on 
the outcome, we calculated effect sizes for the follow-up outcome data by adjusting for 
baseline differences.
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Risk of Bias Assessment
Study quality was assessed using adapted Cochrane risk-of-bias variables [20]. Each 
intervention was evaluated for participant selection (sequence generation, allocation 
concealment), blinding (personnel, outcome assessors), and attrition bias (intent to treat 
[ITT], differences between those lost and retained, overall retention [≥ 80% vs. <80%], 
differential attrition [≤ 10% vs. >10%]). Each item was scored as either high or unclear risk 
of bias (0) or low risk of bias (1). Overall study quality was scored from 0 to 8, with a higher 
score indicating a lower risk of bias.
Data Analysis
Standard meta-analytical methods were used [21, 22]. Effect sizes were estimated using 
odds ratios (OR) because the majority of the studies reported dichotomous outcomes. For 
studies reporting means and standard deviation (SD) values on continuous outcomes, 
standardized mean differences were calculated and converted into OR values [21, 22]. 
Random-effects models with two-tailed tests were used to calculate aggregated effects for 
all outcomes of interest [23]. For HIV transmission risk outcomes, an OR < 1 indicates a 
greater reduction in odds of reporting sex without condoms, multiple sex partners, STD, 
needle sharing, or injection drug use in the intervention group, relative to the comparison 
group. For HIV engagement and medication adherence outcomes, an OR > 1 indicates a 
greater increase in odds of being retained in HIV care, being on ART, adhering to HIV 
medication, or having an undetectable viral load in the intervention group, relative to the 
comparison group.
The magnitude of heterogeneity of the effect sizes was tested using the Q statistic, for which 
a significant result indicates the existence of heterogeneity, and I2 statistic, which quantifies 
the percentage of variation across studies that was due to heterogeneity [24]. For outcomes 
that had a significant Q statistic or moderate to high levels of heterogeneity (I2 ≥50), we 
conducted stratified analyses to assess the impact of intervention as well as study design 
characteristics on the outcomes to further explore the heterogeneity when there were 
sufficient numbers of studies (> 6). Specifically, we assessed between-group differences 
(QB) using the mixed-effects model [22] to determine whether intervention and study design 
characteristics were associated with effect sizes. There were a limited number of studies for 
specific subgroups of PLWH and thus stratified analyses were not conducted by participant 
characteristics. All the analyses were carried out using the Comprehensive Meta-Analysis 
software (version 2) [25]. Meta-regression was considered, but not used due to a small 
number of stratified variables with significant between-group differences.
Sensitivity analyses were conducted to test the robustness of the findings. We removed one 
study at a time from each set of aggregated analyses to determine if any one study affected 
the aggregated effect size. Additionally, we re-did the analyses with the longest follow-up 
time point available from each study to determine if the findings were stable at time points 
farther removed from the intervention. Publication bias was ascertained by inspection of a 
funnel plot of standard error estimates versus effect-size estimates and by a linear regression 
test [22, 26].
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RESULTS
The study selection process is summarized in Figure 1. Among 148 intervention studies that 
were specifically designed for PLWH in the U.S., 15 RCTs, consisting of 4,487 PLWH, met 
the inclusion criteria (see Supplementary Materials F for excluded studies).
Overall Characteristics of Integrated Interventions for PLWH in the United States
Table 1 provides brief descriptive characteristics of the 15 integrated interventions. 
Interventions targeted a variety of PLWH subgroups, including (not mutually exclusive) 
clinic patients [27-32], youth or young adults [31-33], persons who use/inject drugs [30, 33, 
34], women [35, 36], inmates reentering the community [37, 38], women with histories of 
sexual abuse [36], persons who were homeless or at risk of homelessness [39] and other 
high-risk PLWH (e.g., persons who engaged in unprotected sex with HIV-negative/status 
unknown partners or had medication/visit adherence problems) [28, 31, 40].
Regarding the intervention characteristics, nine studies addressed risk reduction and 
medication adherence [29-32, 35, 36, 38, 40, 41], four studies examined all three behaviors 
[33, 34, 37, 39], and two studies focused on HIV care engagement and medication 
adherence [27, 28]. Almost half of the interventions were tailored to an individual's needs by 
using less structured sessions [27-29, 31, 32, 35, 38]. The majority of the interventions were 
delivered oneon-one [27-29, 31-33, 37, 39, 40] and in settings where PLWH receive services 
or care (e.g., HIV outpatient clinics, community AIDS service centers, methadone treatment 
clinics) [27-32, 35, 40, 41]. Interventions were delivered by trained facilitators [27, 28, 34, 
36, 37, 39-41] or by health care providers or counselors [30-33, 35, 38]. One was a 
computer-delivered intervention [29]. The number of intervention sessions ranged from 3 to 
48 with a median of 8 sessions. The median time per session was 90 minutes (range: 30 to 
120 minutes per session) and the median total time of the interventions was 10.5 hours 
(range: 2 to 96 hours).
Regarding the study design and quality, the sample sizes ranged from 56 to 966 with a 
median of 175 participants. Five studies [29, 34, 39-41] conducted power analyses to 
estimate the sample sizes needed for detecting moderate effect sizes. Although all studies 
were RCTs, the level of risk of bias varied (see Supplementary Material F). Out of 8 risk of 
bias variables, seven RCTs scored 0 to 4 (higher risk of bias), five scored 5, and three scored 
6 to 7 (lower risk of bias). The majority of studies retained > 80% of participants (12 
studies) and had differential retention < 10% (12 studies). The most common risk of bias 
was not clearly reporting blinding, ITT, or allocation concealment.
Efficacy of Integrated Interventions
Figure 2 presents the aggregated effect sizes for the nine outcomes related to HIV 
transmission risk, HIV care engagement, and medication adherence. Overall, PLWH 
receiving integrated interventions were significantly less likely than comparison participants 
to report sex without condoms. The intervention effects on HIV medication adherence 
behavior and undetectable viral load approached statistical significance. No significant 
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intervention effects were observed for number of sex partners, STD, needle sharing, 
injection drug use, retention in HIV care, and being on ART.
Heterogeneity, Sensitivity Tests, and Publication Bias
As seen in Figure 2, four out of nine outcomes (i.e., sex without condoms, number of sex 
partners, medication adherence, undetectable viral load) had significant Q statistics or a 
moderate to high level of heterogeneity across studies (I2 > 50). Sensitivity tests did not 
reveal any single study that exerted influence on the overall effect size for the majority of 
outcomes, except for medication adherence behavior. Excluding either one of the two 
studies [33, 39] made the overall intervention effect on the medication adherence behavior 
significant (OR = 1.48, 95% CI = 1.11, 1.97, p = 0.007 when removed [39]; OR = 1.44, 95% 
CI = 1.04, 1.98, p = 0.028 when removed [33]). However, neither study significantly 
reduced the overall heterogeneity. Additional sensitivity tests using the longest follow-ups 
when data were available did not significantly change the findings for any of the outcomes 
reported in Figure 2.
Based on the inspection of funnel plots and the linear regression tests, there was no evidence 
that our effect-size estimates for sex without condoms, medication adherence behavior, and 
undetectable viral load were influenced by non-inclusion of studies with non-significant 
findings.
Stratified Analysis
The results of stratified analyses for sex without condoms, medication adherence behavior, 
and undetectable viral load are presented in Table 2. When comparing intervention groups to 
comparison groups, significant intervention effects on at least two of three outcomes were 
seen in RCTs that were tailored to individual needs (for all three outcomes), delivered one-
on-one (for sex without condoms and undetectable viral load), delivered in settings where 
PLWH receive services or care (for sex without condoms and medication adherence), had 
more than 4 sessions (for sex without condoms and medication adherence), had lower risk of 
bias (for sex without condoms and undetectable viral load), and used standard of care or 
wait list control (for sex without condoms and undetectable viral load). The QB statistics 
showed that several (but not all) intervention and study design characteristics remained 
statistically significant.
Discussion
This meta-analysis is the first to focus on integrated interventions for PLWH. Our findings 
show that integrated interventions are effective in reducing sex without condoms and 
potentially improve medication adherence behavior and undetectable viral load. The overall 
intervention effects on sex without condoms (OR, 0.74), medication adherence (OR, 1.35), 
and undetectable viral load (OR, 1.46) observed in this meta-analysis were comparable to 
the magnitude of effect sizes observed in previously published meta-analyses of RCTs for 
PLWH (sex without condoms: OR, 0.57 [8]; sex without condoms with at-risk partners: OR, 
0.79 [11]; medication adherence: OR, 1.50 [16]; undetectable viral load: OR, 1.25 [16]). 
Results indicate no evidence that integrated interventions have effects on changing the 
number of sex partners, STD, needle sharing, injection drug use, retention in HIV care, or 
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being on ART. The lack of evidence on these outcomes might imply that some behaviors are 
more difficult to change [9, 13, 14]. Alternatively, addressing multiple behavioral targets 
simultaneously may dilute the intervention effect on some of these outcomes, especially 
when the problem behaviors do not share common influencing factors that the interventions 
were intended to address. Due to few studies evaluating the outcomes that show null results, 
the findings need to be reassessed when additional data become available.
Aside from overall intervention effects, stratified analyses indicated several patterns that 
deserve attention. The effect sizes tended to be significant in interventions that were tailored 
to individual needs, delivered one-on-one, or delivered in settings where PLWH receive 
services or care. These findings corroborate previous meta-analysis findings on sexual risk 
behavior [8] and the recently released recommendations for HIV prevention with adults and 
adolescents with HIV in the United States by CDC, HRSA and NIMH [3]. Additionally, 
studies using standard of care or wait list control were more likely than studies using 
demand or attention control to show stronger intervention effects on sex without condoms 
and undetectable viral load. For HIV-related comparison groups, using variations of the 
interventions as comparison groups may greatly reduce the ability to detect intervention 
effects [42]. Using a standardized comparison arm that the HIV prevention field could agree 
upon as a prevention standard can facilitate comparing intervention effects across studies.
Our findings must be viewed within the context of the limitations of the available evidence 
and point to further research needs. While interventions were designed for PLWH and some 
specifically targeted subgroups of PLWH, there were a limited number of studies to further 
examine which intervention strategies work best for specific groups. Given that MSM and 
transgender women are disproportionately affected by HIV [1], it is important to further 
evaluate whether the strategies identified here work well within these groups and to 
determine what additional strategies may be effective in improving prevention and care 
outcomes for these most affected groups. Another limitation is that not all included studies 
clearly reported blinding, ITT, or allocation concealment. Improving reporting of RCTs by 
following the CONSORT statement [43] and implementing strategies to reduce the risk of 
bias [44] would further facilitate evaluation of HIV prevention research. Similarly, 
improving reporting of serostatus of partners can provide better data for assessing 
seroadaptive strategies practiced by PLWH and determining the level of risk that sexual 
behaviors pose for HIV transmission. Self-reported outcomes, such as sex without condoms 
and medication adherence, may be open to socially desirable responding. This might 
contribute to the difference in effectiveness observed on different outcomes. Acknowledging 
the possibility of self-reported bias, many studies attempted to ensure confidentiality of data 
by using computer-assisted assessments. In addition, all studies had a comparison group and 
randomly assigned participants which may reduce the likelihood that impression 
management, the driver of socially desirable responding, influenced the intervention effect.
Our meta-analysis is intended to examine a fundamental question – are integrated 
interventions effective in improving prevention and care outcomes? Whether integrated 
interventions are more “optimal” than single-target interventions is an important question, 
but it is beyond the scope of this systematic review. From an experimental research point of 
view, a single-target intervention can inform what works for changing one behavior at a 
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time. However, using single-target interventions to address multiple problem behaviors may 
require more resources (i.e., more sessions) and time. Integrated interventions, on the other 
hand, can be more practical and closer to the reality of regular programmatic practices in the 
field. There are a few important implementation questions to consider for better informing 
best practices: Would the implementation of integrated interventions yield more favorable 
prevention and care outcomes than the use of bundled single-target interventions? What 
contributes to the synergistic effects of integrated interventions that are not available in 
single-target interventions? What are the optimal ways to combine integrated interventions 
with biomedical and structural interventions to reach NHAS prevention and care goals [1]?
In conclusion, we found evidence of benefits of integrated interventions on some HIV 
transmission risk behavior and medication adherence outcomes for PLWH. Insufficient 
evidence was found for STD, needle sharing, injection drug use, and HIV care engagement 
partially because of a limited number of studies. When selecting integrated interventions for 
PLWH, prevention providers may consider the effective intervention strategies identified in 
this meta-analysis. How to incorporate integrated interventions with other combination HIV 
prevention strategies, such as biomedical and structural interventions, to reach the optimal 
HIV prevention and care outcomes among PLWH requires further research.
Supplementary Material
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Acknowledgements
We thank other members of the HIV/AIDS Prevention Research Synthesis (PRS) Project members for their 
contribution to the coding and maintenance of the PRS database that was used for this systematic review (listed 
alphabetically): Adebukola Adegbite, Terrika Barham, Julia B. DeLuca, Theresa A. Sipe, Maria Luisa Tungol, H. 
Waverly Vosburgh, and Christina White. We also thank the following authors who provided additional analysis for 
our review: Maria Holstad, Ann Kurth, Mary Jane Rotheram-Borus/W. Scott Comulada/Steve Morin, and David 
Purcell/Yuko Mizuno.
Financial support. This work was supported by the Division of HIV/AIDS Prevention at the U.S. Centers for 
Disease Control and Prevention and was not funded by any other organization.
Reference List
1. National Office on AIDS Policy. National HIV/AIDS strategy for the United States: Updated to 
2020. Available at: http://www.aids.gov/federal-resources/national-hiv-aids-strategy/nhas-
update.pdf. Published July 30, 2015. [Accessed 30 July 2015]
2. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care 
objectives by using HIV surveillance data - United States and 6 dependent areas - 2013. 2015; 20(2) 
Available at: http://www.cdc.gov/hiv/library/reports/surveillance/. Published July 2015. [Accessed 
24 August 2015]. 
3. Centers for Disease Control and Prevention, Health Resources and Services Administration, 
National Institutes of Health, American Academy of HIV Medicine, Association of Nurses in AIDS 
Care, International Association of Providers in AIDS Care, the National of Minority AIDS Council, 
and Urban Coalition for HIV/AIDS Prevention Services. Recommendations for HIV Prevention 
with Adults and Adolescents with HIV in the United States. 2014. Available at: http://
stacks.cdc.gov/views/cdc/26062. [Accessed 6 February 2015]
Crepaz et al. Page 9
AIDS. Author manuscript; available in PMC 2016 November 28.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
4. Metsch LR, Pereyra M, Messinger S, Del RC, Strathdee SA, Anderson-Mahoney P, et al. HIV 
transmission risk behaviors among HIV-infected persons who are successfully linked to care. Clin 
Infect Dis. 2008; 47:577–584. [PubMed: 18624629] 
5. Remien RH, Dolezal C, Wagner GJ, Goggin K, Wilson IB, Gross R, et al. The association between 
poor antiretroviral adherence and unsafe sex: differences by gender and sexual orientation and 
implications for scale-up of treatment as prevention. AIDS Behav. 2014; 18:1541–1547. [PubMed: 
24213215] 
6. Munene E, Ekman B. Association between patient engagement in HIV care and antiretroviral 
therapy medication adherence: cross-sectional evidence from a regional HIV care center in Kenya. 
AIDS Care. 2014; 27:1–9. [PubMed: 25117749] 
7. McNairy ML, El-Sadr WM. Antiretroviral therapy for the prevention of HIV transmission: what 
will it take? Clin Infect Dis. 2014; 58:1003–1011. [PubMed: 24429438] 
8. Crepaz N, Lyles CM, Wolitski RJ, Passin WF, Rama SM, Herbst JH, et al. Do prevention 
interventions reduce HIV risk behaviours among people living with HIV? A meta-analytic review 
of controlled trials. AIDS. 2006; 20:143–157. [PubMed: 16511407] 
9. Johnson BT, Carey MP, Chaudoir SR, Reid AE. Sexual risk reduction for persons living with HIV: 
research synthesis of randomized controlled trials, 1993 to 2004. J Acquir Immune Defic Syndr. 
2006; 41:642–650. [PubMed: 16652039] 
10. Kennedy CE, Medley AM, Sweat MD, O'Reilly KR. Behavioural interventions for HIV positive 
prevention in developing countries: a systematic review and meta-analysis. Bull World Health 
Organ. 2010; 88:615–623. [PubMed: 20680127] 
11. Yin L, Wang N, Vermund SH, Shepherd BE, Ruan Y, Shao Y, et al. Sexual risk reduction for 
HIV-infected persons: a meta-analytic review of “positive prevention” randomized clinical trials. 
PLoS One. 2014; 9:e107652. [PubMed: 25243404] 
12. Crepaz N, Tungol-Ashmon MV, Higa DH, Vosburgh W, Mullins MM, Barham T, et al. A 
systematic review of interventions for reducing HIV risk behaviors among people living with HIV 
in the United States, 1988-2012. AIDS. 2014; 28:633–656. [PubMed: 24983541] 
13. Higa DH, Marks G, Crepaz N, Liau A, Lyles CM. Interventions to improve retention in HIV 
primary care: a systematic review of U.S. studies. Curr HIV/AIDS Rep. 2012; 9:313–325. 
[PubMed: 22996171] 
14. Liau A, Crepaz N, Lyles CM, Higa DH, Mullins MM, DeLuca J, et al. Interventions to promote 
linkage to and utilization of HIV medical care among HIV-diagnosed persons: a qualitative 
systematic review, 1996-2011. AIDS Behav. 2013; 17:1941–1962. [PubMed: 23456593] 
15. de Bruin M, Viechtbauer W, Schaalma HP, Kok G, Abraham C, Hospers HJ. Standard care impact 
on effects of highly active antiretroviral therapy adherence interventions: A meta-analysis of 
randomized controlled trials. Arch Intern Med. 2010; 170:240–250. [PubMed: 20142568] 
16. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in 
improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-
analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006; 43(Suppl 
1):S23–S35. [PubMed: 17133201] 
17. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a 
research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006; 41:285–297. 
[PubMed: 16540929] 
18. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and 
meta-analyses: the PRISMA statement. PLoS Med. 2009; 6:e1000097. [PubMed: 19621072] 
19. Prevention Research Synthesis (PRS) Project. Compendium of evidence based HIV behavioral 
interventions. Available at: http://www.cdc.gov/hiv/prevention/research/compendium/index.html. 
[Accessed 6 February 2015]
20. Higgins, J.; Green, S., editors. Cochrane Handbook for Systematic Reviews of Interventions 
Version 5.1.0 [updated March 2011].. The Cochrane Collaboration. Available at: http://
handbook.cochrane.org. [Accessed 6 February 2015]
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177–188. 
[PubMed: 3802833] 
22. Lipsey, MW.; Wilson, DB. Practical Meta-analysis. Sage; Thousand Oaks, California: 2001. 
Crepaz et al. Page 10
AIDS. Author manuscript; available in PMC 2016 November 28.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
23. Hedges LV, Vevea JL. Fixed and random effects models in meta-analysis. Psychol Methods. 1998; 
3:486–504.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. 
BMJ. 2003; 327:557–560. [PubMed: 12958120] 
25. Comprehensive Meta-analysis [computer program]. Version 2. Available at: http://www.meta-
analysis.com/index.php. [Accessed 1 September 2015]
26. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, 
graphical test. BMJ. 1997; 315:629–634. [PubMed: 9310563] 
27. Konkle-Parker DJ, Erlen JA, Dubbert PM, May W. Pilot testing of an HIV medication adherence 
intervention in a public clinic in the Deep South. J Am Acad Nurse Pract. 2012; 24:488–498. 
[PubMed: 22845032] 
28. Konkle-Parker DJ, Amico KR, McKinney VE. Effects of an intervention addressing information, 
motivation, and behavioral skills on HIV care adherence in a southern clinic cohort. AIDS Care. 
2014; 26:674–683. [PubMed: 24116922] 
29. Kurth AE, Spielberg F, Cleland CM, Lambdin B, Bangsberg DR, Frick PA, et al. Computerized 
counseling reduces HIV-1 viral load and sexual transmission risk: findings from a randomized 
controlled trial. J Acquir Immune Defic Syndr. 2014; 65:611–620. [PubMed: 24384803] 
30. Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J. A randomized clinical trial of a 
manual-guided risk reduction intervention for HIV-positive injection drug users. Health Psychol. 
2003; 22:223–228. [PubMed: 12683743] 
31. Naar-King S, Parsons JT, Murphy DA, Chen X, Harris DR, Belzer ME. Improving health 
outcomes for youth living with the human immunodeficiency virus: a multisite randomized trial of 
a motivational intervention targeting multiple risk behaviors. Arch Pediatr Adolesc Med. 2009; 
163:1092–1098. [PubMed: 19996045] 
32. Naar-King S, Wright K, Parsons JT, Frey M, Templin T, Lam P, et al. Healthy choices: 
motivational enhancement therapy for health risk behaviors in HIV-positive youth. AIDS Educ 
Prev. 2006; 18:1–11. [PubMed: 16539572] 
33. Rotheram-Borus MJ, Swendeman D, Comulada WS, Weiss RE, Lee M, Lightfoot M. Prevention 
for substance-using HIV-positive young people: telephone and in-person delivery. J Acquir 
Immune Defic Syndr. 2004; 37(Suppl 2):S68–S77. [PubMed: 15385902] 
34. Purcell DW, Latka MH, Metsch LR, Latkin CA, Gomez CA, Mizuno Y, et al. Results from a 
randomized controlled trial of a peer-mentoring intervention to reduce HIV transmission and 
increase access to care and adherence to HIV medications among HIV-seropositive injection drug 
users. J Acquir Immune Defic Syndr. 2007; 46(Suppl 2):S35–S47. [PubMed: 18089983] 
35. Holstad MM, DiIorio C, Kelley ME, Resnicow K, Sharma S. Group motivational interviewing to 
promote adherence to antiretroviral medications and risk reduction behaviors in HIV infected 
women. AIDS Behav. 2011; 15:885–896. [PubMed: 21165692] 
36. Wyatt GE, Longshore D, Chin D, Carmona JV, Loeb TB, Myers HF, et al. The efficacy of an 
integrated risk reduction intervention for HIV-positive women with child sexual abuse histories. 
AIDS Behav. 2004; 8:453–462. [PubMed: 15690118] 
37. MacGowan RJ, Lifshay J, Mizuno Y, Johnson WD, McCormick L, Zack B. Positive Transitions 
(POST): evaluation of an HIV prevention intervention for HIV-positive persons releasing from 
correctional facilities. AIDS Behav. 2014; 19:1061–1069. [PubMed: 25190222] 
38. Reznick OG, McCartney K, Gregorich SE, Zack B, Feaster DJ. An ecosystem-based intervention 
to reduce HIV transmission risk and increase medication adherence among inmates being released 
to the community. J Correct Health Care. 2013; 19:178–193. [PubMed: 23657796] 
39. Wolitski RJ, Kidder DP, Pals SL, Royal S, Aidala A, Stall R, et al. Randomized trial of the effects 
of housing assistance on the health and risk behaviors of homeless and unstably housed people 
living with HIV. AIDS Behav. 2010; 14:493–503. [PubMed: 19949848] 
40. Healthy Living Project Team. Effects of a behavioral intervention to reduce risk of transmission 
among people living with HIV: the healthy living project randomized controlled study. J Acquir 
Immune Defic Syndr. 2007; 44:213–221. [PubMed: 17146375] 
Crepaz et al. Page 11
AIDS. Author manuscript; available in PMC 2016 November 28.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
41. Kalichman SC, Cherry C, Kalichman MO, Amaral CM, White D, Pope H, et al. Integrated 
behavioral intervention to improve HIV/AIDS treatment adherence and reduce HIV transmission. 
Am J Public Health. 2011; 101:531–538. [PubMed: 21233431] 
42. Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: 
challenges in HIV prevention research. AIDS. 2010; 24:621–635. [PubMed: 20179575] 
43. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting 
parallel group randomized trials. Ann Intern Med. 2010; 152:726–732. [PubMed: 20335313] 
44. de Bruin M. Risk of bias in randomised controlled trials of health behaviour change interventions: 
Evidence, practices and challenges. Psychol Health. 2015; 30:1–7. [PubMed: 25223823] 
Crepaz et al. Page 12
AIDS. Author manuscript; available in PMC 2016 November 28.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
PRISMA flow diagram of study selection process, 1996 to 2014
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Figure 2. 
Effects of Integrated Interventions on 9 outcomes: sex without condoms, number of sex 
partners, self-reported STD, needle sharing, injection drug use, retention in HIV care, being 
on ART, medication adherence and undetectable viral load. Abbreviation: OR, odds ratio; 
CI, confidence interval; ART, antiretroviral therapy.
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